Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

Ian Chau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0286-8703; OpenAlex author ID A5025120810. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. Co-author DOI 10.3390/cancers18101597↗
  2. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  3. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  4. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. First author DOI 10.1080/13543784.2021.1995354↗
  5. Targeting the Stroma in the Management of Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.691185↗
  6. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  7. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  8. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … Co-author DOI 10.1080/14737140.2017.1369882↗
  9. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  10. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Last author DOI 10.18632/oncotarget.7208↗
  11. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/meta… Co-author DOI 10.1093/annonc/mdu581↗
  12. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Last author DOI 10.1016/j.clcc.2014.09.005↗
  13. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancre… Last author DOI 10.1016/j.ejca.2014.02.003↗
  14. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. Last author DOI 10.1097/mpa.0b013e31826c6aee↗
  15. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr317↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Cunningham · 7 shared papers, 2012–2026 · strength 0.54
  2. Byung Woog Kang · 2 shared papers, 2021 · strength 0.50
  3. Naureen Starling · 5 shared papers, 2012–2026 · strength 0.44
  4. David J. Watkins · 5 shared papers, 2012–2021 · strength 0.25
  5. David Goldstein · 3 shared papers, 2017–2022 · strength 0.25
  6. Katharine L. Aitken · 1 shared paper, 2026 · strength 0.24
  7. Ricky Harminder Bhogal · 1 shared paper, 2026 · strength 0.24
  8. Kai Tai Derek Yeung · 1 shared paper, 2026 · strength 0.24
  9. Penelope Edwards · 1 shared paper, 2021 · strength 0.22
  10. Florian Lordick · 2 shared papers, 2017–2022 · strength 0.19
  11. Timothy Jay Price · 2 shared papers, 2017–2022 · strength 0.19
  12. Eva Segelov · 2 shared papers, 2017–2022 · strength 0.19
  13. Lorraine A. Chantrill · 2 shared papers, 2017–2022 · strength 0.19
  14. Khurum Hayat Khan · 3 shared papers, 2014–2019 · strength 0.15
  15. Sing Yu Moorcraft · 3 shared papers, 2014–2019 · strength 0.15
  16. Nigel Balfour Jamieson · 2 shared papers, 2019–2021 · strength 0.14
  17. Matteo Fassan · 2 shared papers, 2016–2021 · strength 0.13
  18. Chiara Braconi · 2 shared papers, 2016–2021 · strength 0.13
  19. Nick Pavlakis · 1 shared paper, 2022 · strength 0.13
  20. Amitesh Chandra Roy · 1 shared paper, 2022 · strength 0.13
  21. Trevor Leong · 1 shared paper, 2022 · strength 0.13
  22. Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13
  23. Christos Stelios Karapetis · 1 shared paper, 2022 · strength 0.13
  24. Niall Christopher Tebbutt · 1 shared paper, 2022 · strength 0.13
  25. Mike Nguyen · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.